- Home
- SCLXW vs SLF Comparison
SCLXW vs SLF Comparison
Compare SCLXW & SLF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCLXW
- SLF
- Stock Information
- Founded
- SCLXW N/A
- SLF 1871
- Country
- SCLXW United States
- SLF Canada
- Employees
- SCLXW 115
- SLF N/A
- Industry
- SCLXW Biotechnology: Pharmaceutical Preparations
- SLF Advertising
- Sector
- SCLXW Health Care
- SLF Consumer Discretionary
- Exchange
- SCLXW Nasdaq
- SLF Nasdaq
- Market Cap
- SCLXW N/A
- SLF N/A
- IPO Year
- SCLXW N/A
- SLF N/A
- Fundamental
- Price
- SCLXW $0.07
- SLF $59.94
- Analyst Decision
- SCLXW
- SLF
- Analyst Count
- SCLXW 0
- SLF 0
- Target Price
- SCLXW N/A
- SLF N/A
- AVG Volume (30 Days)
- SCLXW 4.0K
- SLF 434.0K
- Earning Date
- SCLXW 03-07-2025
- SLF 05-08-2025
- Dividend Yield
- SCLXW N/A
- SLF 3.96%
- EPS Growth
- SCLXW N/A
- SLF N/A
- EPS
- SCLXW N/A
- SLF 3.65
- Revenue
- SCLXW $55,152,000.00
- SLF $23,006,727,641.00
- Revenue This Year
- SCLXW N/A
- SLF N/A
- Revenue Next Year
- SCLXW N/A
- SLF $4.18
- P/E Ratio
- SCLXW N/A
- SLF $16.42
- Revenue Growth
- SCLXW 22.02
- SLF 7.30
- 52 Week Low
- SCLXW $0.18
- SLF $46.41
- 52 Week High
- SCLXW $0.18
- SLF $62.85
- Technical
- Relative Strength Index (RSI)
- SCLXW N/A
- SLF 62.50
- Support Level
- SCLXW N/A
- SLF $56.08
- Resistance Level
- SCLXW N/A
- SLF $60.34
- Average True Range (ATR)
- SCLXW 0.00
- SLF 0.77
- MACD
- SCLXW 0.00
- SLF 0.21
- Stochastic Oscillator
- SCLXW 0.00
- SLF 82.92
About SCLXW Scilex Holding Company
Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.